NEW YORK - Na taʻua e Immunocore i le Aso Gafua o le a faʻatau atu 3,733,333 sea i totonu o se maliega faʻatupeina faʻapitoa (PIPE) lea e faʻamoemoe e siitia ai le $ 140 miliona.
I lalo o le maliliega, o le a faʻatau atu e Immunocore ana faʻatauga masani ma faʻatauga masani e le palota mo le $ 37.50 i le sea. O le aufaipisinisi o loʻo i ai nei a le kamupani o loʻo auai i le faʻatupeina e aofia ai le RTW Investments, Rock Springs Capital ma General Atlantic. O le maliega a le PIPE e faʻamoemoe e faʻamutaina i le aso 20 o Iulai.
O le a faʻaaogaina e le kamupani le tupe maua e faʻatupe ai ana sui o le paipa faʻamaʻi ma faʻamaʻi pipisi, e aofia ai le atinaʻeina o lona taʻitaʻia oncology sui, Kimmtrak (tebentafusp-tebn), e togafitia ai le HLA-A * 02: 01 lelei paʻu ma le uveal melanoma.
O lenei tausaga, ua faʻatagaina Kimmtrak mo le faʻaaogaina i tagata mamaʻi ma HLA-A * 02: 01 lelei e le mafai ona faʻaaogaina poʻo metastatic uveal melanoma i le US, Europa ma Peretania, faatasi ai ma isi atunuu. Immunocore faʻaauau ona suʻesuʻeina le vailaʻau i se suʻesuʻega Vaega I / II i le HLA-A * 02: 01-positive cutaneous melanoma.
O lo'o fa'atupuina fo'i e le Immunocore isi sui fa'apitoa e to'afa, e aofia ai ma isi vaila'au fa'aopoopo e lua o le T-cell receptor i le Vaega I/II fa'ata'ita'iga i tumo malō maualuluga.O se tasi o vaila'au o lo'o atia'e mo le HLA-A*02:01-positive ma MAGE-A4-positive ma'i, ma isi sini HLA-A*02:01 ma PRAME-positive tumors.
Privacy Policy.terms and Conditions.Copyright © 2022 GenomeWeb, se iunite pisinisi a Crain Communications. aia tatau uma ua taofia.